PT - JOURNAL ARTICLE AU - Begnel, Emily R. AU - Chohan, Bhavna H. AU - Ojee, Ednah AU - Adhiambo, Judith AU - Owiti, Prestone AU - Ogweno, Vincent AU - Holland, LaRinda A. AU - Fish, Carolyn S. AU - Richardson, Barbra A. AU - Khan, Adam K. AU - Maqsood, Rabia AU - Lim, Efrem S. AU - Lehman, Dara A. AU - Slyker, Jennifer AU - Kinuthia, John AU - Wamalwa, Dalton AU - Gantt, Soren TI - HIV and SARS-CoV-2 infection in postpartum Kenyan women and their infants AID - 10.1101/2022.06.23.22276827 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.23.22276827 4099 - http://medrxiv.org/content/early/2022/06/27/2022.06.23.22276827.short 4100 - http://medrxiv.org/content/early/2022/06/27/2022.06.23.22276827.full AB - Background HIV may increase SARS-CoV-2 infection risk and COVID-19 severity generally, but data are limited about its impact on postpartum women and their infants. As such, we characterized SARS-CoV-2 infection among mother-infant pairs in Nairobi, Kenya.Methods We conducted a nested study of 53 HIV-uninfected and 51 healthy women living with HIV, as well as their HIV-exposed uninfected (N=41) and HIV-unexposed (N=48) infants, participating in a prospective cohort. SARS-CoV-2 serology was performed on plasma collected between 1 May-31 December 2020 to determine the incidence, risk factors, and symptoms of infection. SARS-CoV-2 RNA PCR and sequencing was also performed on stool samples from seropositive participants.Results SARS-CoV-2 seropositivity was found in 38% of the 104 mothers and in 17% of the 89 infants. There was no significant association between SARS-CoV-2 infection and maternal HIV (Hazard Ratio [HR]=1.51, 95% CI: 0.780-2.94) or infant HIV exposure (HR=1.48, 95% CI: 0.537-4.09). Maternal SARS-CoV-2 was associated with a >10-fold increased risk of infant infection (HR=10.3, 95% CI: 2.89-36.8). Twenty percent of participants had symptoms, but no participant experienced severe COVID-19 or death. Seroreversion occurred in ∼30% of mothers and infants. SARS-CoV-2 sequences obtained from stool were related to contemporaneously circulating variants.Conclusions These data indicate that postpartum Kenyan women and their infants were at high risk for SARS-CoV-2 infection in 2020, and that antibody responses waned rapidly. However, most cases were asymptomatic and healthy women living with HIV did not have a substantially increased risk of infection or severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Canadian Institutes of Health Research (COVID-19 May 2020 Rapid Research Funding Opportunity Operating Grant 202005, Project Grant 201709 to SG) and the US National Institutes of Health (grant numbers R01HD092311 to DAL and R00DK107923 to ESL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Washington gave ethical approval for this work. The Ethics and Research Committee of the Kenyatta National Hospital / University of Nairobi gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data required for this analysis were collected from human research participants and contain a set of sufficiently identifying variables, including dates of birth, that cannot be shared publicly per ethical guidance.